Analysts See $-0.27 EPS for KalVista Pharmaceuticals, Inc. (KALV)

September 8, 2018 - By Catherine Diaz

Analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report $-0.27 EPS on September, 13.They anticipate $0.24 EPS change or 47.06 % from last quarter’s $-0.51 EPS. After having $-0.06 EPS previously, KalVista Pharmaceuticals, Inc.’s analysts see 350.00 % EPS growth. The stock decreased 3.36% or $0.61 during the last trading session, reaching $17.54. About 87,947 shares traded or 70.26% up from the average. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has risen 26.79% since September 8, 2017 and is uptrending. It has outperformed by 14.22% the S&P500.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company has market cap of $290.80 million. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. It currently has negative earnings. The Company’s products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein.

More notable recent KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news were published by: Benzinga.com which released: “50 Biggest Movers From Yesterday” on August 22, 2018, also Benzinga.com with their article: “41 Biggest Movers From Yesterday” published on August 21, 2018, Benzinga.com published: “The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace’s Offering, Dexcom Buys TypeZero” on August 23, 2018. More interesting news about KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) were released by: Seekingalpha.com and their article: “KalVista Pharmaceuticals prices public offering of common stock” published on September 06, 2018 as well as Seekingalpha.com‘s news article titled: “KalVista Pharma readies stock offering” with publication date: September 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.